Curated News
By: NewsRamp Editorial Staff
January 17, 2025
Soligenix Targets Psoriasis with New Therapy SGX302
Discuss on Reddit
Substack
Telegram
GithubTLDR
- Soligenix, Inc. targets psoriasis treatment with SGX302, offering a competitive edge in the $40 billion global treatment market.
- SGX302 treatment by Soligenix uses photodynamic light therapy and synthetic hypericin to target dysregulated T-cells in psoriasis patients.
- Soligenix's SGX302 treatment for psoriasis improves quality of life by reducing symptoms and providing a much-needed approach to treating the condition.
- Psoriasis affects 125 million worldwide, with SGX302 showing promising results in clinical studies, offering hope for better treatment outcomes.
Impact - Why it Matters
This news matters because psoriasis is a widespread condition that can significantly impact a patient's quality of life. Soligenix's innovative approach with SGX302 offers hope for those suffering from mild-to-moderate psoriasis, providing a potentially effective treatment option. The success of this therapy could lead to improved outcomes for patients and establish Soligenix as a key player in the treatment of rare diseases.
Summary
Soligenix, Inc., a late-stage biopharmaceutical company, is targeting psoriasis with a new therapy called SGX302. Psoriasis is a chronic skin condition affecting millions worldwide, with symptoms including thick, scaly skin patches. SGX302 utilizes photodynamic light therapy and synthetic hypericin to treat mild-to-moderate psoriasis by targeting T-cells. Clinical studies have shown promising results, with patients experiencing a 50% drop in Psoriasis Activity and Severity Index score.
Source Statement
This curated news summary relied on this press release disributed by News Direct. Read the source press release here, Soligenix Targets Psoriasis with New Therapy SGX302
